What do ER, PR, and HER2 biomarker tests mean in breast cancer

Understanding ER, PR, and HER2 Biomarker Tests

These three tests are fundamental to understanding your breast cancer and determining which treatments are most likely to work for you. Let me break down what each one means.

ER (Estrogen Receptor) Status

What it is: This test checks whether your cancer cells have receptors (think of them as "locks") that respond to the hormone estrogen.

What the results mean:

• ER-positive (ER+): Your cancer cells have estrogen receptors. This means the cancer cells can be stimulated to grow by estrogen in your body. This is actually good news because it opens up treatment options—your doctors can use hormone-blocking therapies to slow or stop growth.
• ER-negative (ER-): Your cancer cells don't have estrogen receptors, so hormone therapy won't be effective for this cancer.

According to the NCCN Guidelines for Patients, ER+ breast cancer is detected when testing finds estrogen hormone receptors in at least 1 out of every 100 cancer cells. There's also a category called "ER-low–positive" where receptors are found in only 1 to 10 out of every 100 cells.

PR (Progesterone Receptor) Status

What it is: Similar to ER testing, this checks for receptors that respond to progesterone, another hormone.

What the results mean:

• PR-positive (PR+): Cancer cells respond to progesterone
• PR-negative (PR-): Cancer cells don't respond to progesterone

Most breast cancers are either ER+/PR+ (both receptors present) or ER+/PR- (only estrogen receptors). An ER-/PR+ tumor is relatively uncommon.

Why it matters: PR status helps your doctors refine treatment decisions. Cancers with both ER and PR receptors often respond well to hormone-blocking therapy.

HER2 (Human Epidermal Growth Factor Receptor 2) Status

What it is: This test checks whether your cancer cells have extra copies of the HER2 gene or produce too much HER2 protein. HER2 is a growth-promoting protein on cancer cells.

What the results mean:

• HER2-positive (HER2+): Your cancer cells have extra HER2, which makes them grow faster. However, this is treatable—there are targeted therapies specifically designed to block HER2 and stop cancer growth.
• HER2-negative (HER2-): Your cancer cells don't have extra HER2

How These Tests Work Together

According to NCCN Guidelines, these biomarkers are identified using special testing methods called immunohistochemistry (IHC) and FISH or ISH. A pathologist examines your biopsy sample under a microscope and adds chemical markers to identify these receptors.

Your cancer will be classified into categories based on combinations:

| Type | ER | PR | HER2 | Treatment Approach | |----------|--------|--------|----------|------------------------| | Hormone Receptor-Positive (HR+) | + | +/- | - | Endocrine (hormone-blocking) therapy | | HER2-Positive | +/- | +/- | + | HER2-targeted therapy | | Triple-Negative | - | - | - | Chemotherapy, immunotherapy |

Why This Matters for Your Care

According to the NCCN Guidelines for Patients, hormone receptor and HER2 status are essential because treatment planning is based on these biomarker results. Knowing your ER, PR, and HER2 status allows your care team to:

• Choose therapies most likely to work for YOUR specific cancer
• Avoid treatments that won't be effective
• Plan for potential side effects
• Discuss prognosis and follow-up care

Questions to Ask Your Care Team

1. What are my specific ER, PR, and HER2 results?
2. What do these results mean for my treatment options?
3. Which treatment approach do you recommend based on my biomarker status?
4. Are there any clinical trials available for my specific biomarker profile?
5. How might these results change my long-term follow-up care?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.